Aravive’s (NASDAQ:ARAV) Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment.
The trial did not show any difference between the two arms in the overall population, which included patients previously treated with bevacizumab. The company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept.
“We are conducting additional analyses on the AXLerate-OC Phase 3 trial to further evaluate the results of this study and determine the best path forward with our two other planned indications,” Gail McIntyre, Ph.D., president and CEO of Aravive said in a statement.
